A Phase II One-arm Open-label Neoadjuvant Study of Pembrolizumab in Combination With Nab-paclitaxel Followed by Pembrolizumab in Combination With Epirubicin and Cyclophosphamide in Patients With Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide; Epirubicin
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms NeoImmunoboost - AGO B-01
- 10 Sep 2018 Status changed from recruiting to suspended.
- 31 Aug 2018 Biomarkers information updated
- 04 Jul 2018 Status changed from not yet recruiting to recruiting.